Omeros Corp
OMER4.260USD
+0.200+4.93%
Fechamento 09/18, 16:00（ET）Cotações atrasadas em 15 min
255.70MValor de mercado
PerdaP/L TTM
Mais detalhes de Omeros Corp Empresa
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Informações da empresa
Código da empresaOMER
Nome da EmpresaOmeros Corp
Data de listagemOct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
Número de funcionários202
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 08
Endereço201 Elliott Avenue West
CidadeSEATTLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal98119
Telefone12066765000
Sitehttps://www.omeros.com/
Código da empresaOMER
Data de listagemOct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David J. Borges
Mr. David J. Borges
Chief Accounting Officer, Vice President - Finance, Treasurer
Chief Accounting Officer, Vice President - Finance, Treasurer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 17 de ago
Atualizado em: dom, 17 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Ingalls & Snyder LLC (Asset Management)
5.85%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
2.98%
D. E. Shaw & Co., L.P.
2.42%
Outro
78.50%
Investidores
Investidores
Proporção
Ingalls & Snyder LLC (Asset Management)
5.85%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
2.98%
D. E. Shaw & Co., L.P.
2.42%
Outro
78.50%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
16.49%
Investment Advisor
15.24%
Hedge Fund
6.07%
Research Firm
3.79%
Individual Investor
3.79%
Bank and Trust
0.88%
Insurance Company
0.12%
Venture Capital
0.09%
Pension Fund
0.05%
Outro
53.47%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
255
30.16M
44.94%
-422.08K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
2023Q2
303
29.52M
46.99%
+306.67K
2023Q1
308
23.79M
37.88%
-4.75M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Ingalls & Snyder LLC (Asset Management)
3.98M
6.79%
-30.05K
-0.75%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.02M
6.87%
+58.15K
+1.47%
Mar 31, 2025
The Vanguard Group, Inc.
3.24M
5.53%
+95.60K
+3.04%
Mar 31, 2025
Demopulos (Gregory A. M.D.)
2.03M
3.46%
--
--
May 23, 2025
D. E. Shaw & Co., L.P.
1.94M
3.31%
+99.63K
+5.42%
Mar 31, 2025
Stifel, Nicolaus & Company, Incorporated
1.56M
2.66%
-24.56K
-1.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.37M
2.34%
+29.70K
+2.22%
Mar 31, 2025
State Street Global Advisors (US)
1.36M
2.31%
+144.57K
+11.93%
Mar 31, 2025
Morgan Stanley & Co. LLC
584.71K
1%
+376.03K
+180.19%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
